Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Novo Nordisk 12.087, Roche 17.1305.
* Roche reports semi-annually. Values are evenly split across both quarters within each half.
Novo Nordisk vs Roche Net Worth and Market Cap
Novo Nordisk (NVO) and Roche (RHHBY) are peers in GLP-1. Novo Nordisk reported revenue of $12.1B as of Q2 2026, compared with $34.3B for Roche. Roche leads on revenue.
Novo Nordisk's gross margin is 78.2% versus 71.7% for Roche. Novo Nordisk's net margin is 26.7% versus 17.9% for Roche.
Key differences
- Revenue growth on the same quarter a year earlier: Novo Nordisk +2.1% (Q2 2026), Roche -4.2% (Q4 2025).
- Novo Nordisk keeps more of its revenue as operating profit: a 34.5% operating margin, against 23.2% at Roche.
- Novo Nordisk's KPIs on Sterling include Next-Generation Obesity: CagriSema + Amycretin Readouts and 2030 Ambitions (Capital Markets Day, 21 Sep 2026).
- Roche's KPIs on Sterling include Carmot Asset Pipeline: CT-388, CT-996, CT-868 Trial Readout Timeline and CT-868 (Acmopatide) Discontinuation.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Novo Nordisk, Roche.| Metric | Novo Nordisk | Roche |
|---|---|---|
| Market Cap | - | - |
| Revenue | $12.09B | $34.26B |
| Cost of Revenue | $2.63B | $9.68B |
| Gross Profit | $9.45B | $24.58B |
| Operating Income | $4.17B | $7.96B |
| Net Income | $3.23B | $6.13B |
| R&D Expense | $2.74B | $7.48B |
| Earnings Per Share | $0.73 | $0.95 |
| Gross Margin | 78.2% | 71.7% |
| Operating Margin | 34.5% | 23.2% |
| Net Profit Margin | 26.7% | 17.9% |
| Free Cash Flow | $6.53B | $10.67B |
| Cumulative Free Cash Flow | $107.39B | $299.34B |
| Operating Cash Flow | $8.50B | $13.12B |
| Cash & Equivalents | $6.85B | $6.32B |